-78%

est. 2Y upside i

HealthcareSeries A

Converge Bio is at the forefront of integrating Generative AI with biological data. Our mission is to empower biotech and pharmaceutical companies to discover and develop more effective drugs faster, utilizing the power of Large Language Models (LLMs) specifically trained on biological languages.

Rank

#3406

Sector

AI in Drug Discovery & Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Medium

Converge Bio operates in a high-growth AI drug discovery market with a substantial TAM, backed by strong investors and early customer traction.

Last updated: March 10, 2026

Bull (10%)+300%

Converge Bio's integrated AI systems achieve significant breakthroughs in multiple therapeutic areas, leading to rapid adoption by major pharma companies beyond initial customers. This drives ARR to $50M+ by 2028, justifying a $480M+ valuation at a 10x revenue multiple, well above the current assumed $120M.

Base (45%)+50%

Converge Bio continues to gain traction with mid-sized biotech and some pharmaceutical clients, growing revenue steadily but facing intense competition from incumbents and other startups. ARR reaches $25M by 2028, leading to a modest valuation increase to $180M, which provides some upside for common shareholders.

Bear (45%)-80%

Incumbents or well-funded competitors launch superior, more integrated solutions, or Converge Bio struggles with the high regulatory hurdles and long sales cycles. Growth stalls, leading to a down round or inability to raise further capital, resulting in a valuation of $24M or less, significantly eroding common stock value given the $30M in liquidation preferences.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Investors have contributed $30M in total funding. In an exit at or below the assumed $120M Series A valuation, these investors would take their $30M back first, significantly impacting common shareholder returns.

Dilution Risk

high

As a Series A company, Converge Bio will likely require multiple additional funding rounds (Series B, C, etc.) to scale, which will lead to significant dilution for early common stock or option holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Converge Bio's shares at this early stage.

View all 3 open roles at Converge Bio →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Converge Bio's data — designed to show you've done your homework.

  • 1

    “Given the significant investments by pharmaceutical giants like Eli Lilly (with Nvidia) and tech giants like Google (DeepMind) in AI for drug discovery, how does Converge Bio plan to differentiate its platform and maintain a competitive edge against these well-resourced incumbents?”

  • 2

    “With 'over a dozen' customers and 40 programs completed, what is the current ARR, and what is the strategy to scale revenue significantly over the next two years, especially considering the long sales cycles in the pharmaceutical industry?”

  • 3

    “As a Series A company with $30M raised, what is the anticipated timeline for future funding rounds, and how is the company thinking about managing potential dilution for early employees, particularly regarding a potential liquidity event?”

Community

Valuation Sentiment

Our model estimates -78% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.